Forbes January 20, 2025
Dileep Rao

Venture capital (VC) thrives on risk. Corporations prioritize stable growth. Top-tier VC firm Andreessen Horowitz (AH) often pushes the boundaries of traditional VC and continuously experiments with new strategies, and pivots quickly when strategies fall short.

New Collaboration

Now, AH and Eli Lilly are rewriting the playbook with a pioneering Biotech Ecosystem Fund. This collaboration has the potential to redefine how Corporate VC (CVC) fuels innovation – not just in biotech, but across emerging industries. Here are three key lessons from this partnership that VCs, CVCs and entrepreneurs can use to build the next wave of unicorns.

#1. Top Unicorn Developers Master Early-Stage Venture Risk

Corporations prioritize consistent and growing cash flow and avoid high risk ventures. In contrast, VCs...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

 
Topics: Investments, Trends
AI Startups: Google DeepMind CEO’s Startup Raises $600 Million
Which Biopharma Startups Made the Cut for INVEST Pitch Perfect?
AI-Drug Design & Medical Education Score Massive Rounds | StartUp Health Insights: Week of Apr 1, 2025
JPMorgan’s Health Unit To Invest In Small Business Health Plans
An AI Biotech Hauls In $600M, Plus More Funding Highlights to Close 1Q 2025

Share This Article